{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:22:13Z","timestamp":1761488533587},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,4,1]]},"DOI":"10.1093\/neuonc\/2.2.114","type":"journal-article","created":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T16:01:39Z","timestamp":1283270499000},"page":"114-119","source":"Crossref","is-referenced-by-count":17,"title":["Myeloablative chemotherapy for recurrent aggressive\noligodendroglioma"],"prefix":"10.1093","volume":"2","author":[{"given":"Gregory","family":"Cairncross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lode","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Salzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Paleologos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Kaminer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2000,4,1]]},"reference":[{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Cairncross, J.G., and Eisenhauer, E.A. (1995) Response\nand control: Lessons from oligodendroglioma. J. Clin.\nOncol.13,2475\n-2476.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Cairncross, J.G., and Macdonald, D.R. (1988)\nSuccessful chemotherapy for recurrent malignant oligodendroglioma.\nAnn. Neurol.23,360\n-364.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Cairncross, G., Macdonald, D., Ludwin, S., Lee, D., Cascino, T.,\nBuckner, J., Fulton, D., Dropcho, E., Stewart, D., Schold, C., Jr., Wainman,\nN., and Eisenhauer, E. (1994) Chemotherapy for anaplastic\noligodendroglioma. J. Clin. Oncol.12,2013\n-2021.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Cairncross, G., Swinnen, L., Stiff, P., Rosenfeld, S., Vaughan, W.,\nPaleologos, N., Kaminer, L., DeAngelis, L., Nimer, S., Dropcho, E., Peterson,\nK., Forsyth, P., Stewart, D., Weaver, S., Lieberman, F., Macdonald, D.,\nRamsay, D., and Smith, A. (1997) High-dose thiotepa with\nhematopoietic reconstitution (deferring radiation) for newly diagnosed\naggressive oligodendroglioma. Proc. Am. Soc. Clin.\nOncol.16,388a\n. (Abstract)","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Cairncross, J.G., Ueki, K., Zlatescu, M.C., Lisle, D.K.,\nFinkelstein, D.M., Hammond, R.R., Silver, J.S., Stark, P.C., Macdonald, D.R.,\nIno, Y., Ramsay, D.A., and Louis, D.N. (1998) Specific genetic\npredictors of chemotherapeutic response and survival in patients with\nanaplastic oligodendrogliomas. J. Natl. Cancer Inst.90,1473\n-1479.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Chamberlain, M.C., and Kormanik, P.A. (1997) Salvage\nchemotherapy with paclitaxel for recurrent oligodendrogliomas. J.\nClin. Oncol.15,3427\n-3432.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Fine, H.A., and Antman, K.H. (1992) High-dose\nchemotherapy with autologous bone marrow transplantation in the treatment of\nhigh grade astrocytomas in adults: Therapeutic rationale and clinical\nexperience. Bone Marrow Transplant.\n10,315\n-321.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Glass, J., Hochberg, F.H., Gruber, M.L., Louis, D.N., Smith, D.,\nand Rattner, B. (1992) The treatment of oligodendrogliomas and\nmixed oligodendrogliomaastrocytomas with PCV cheomotherapy. J.\nNeurosurg.76,741\n-745.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Kim, L., Hochberg, F.H., Thornton, A.F., Harsh, G.R., IV, Patel,\nH., Finkelstein, D., and Louis, D.N. (1996) Procarbazine,\nlomustine, and vincristine (PCV) chemotherapy for grade III and grade IV\noligoastrocytomas. J. Neurosurg.85,602\n-607.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Levin, V.A., Edwards, M.S., Wright, D.C., Seager, M.L., Schimberg,\nT.P., Townsend, J.J., and Wilson, C.B. (1980) Modified\nprocarbazine, CCNU, and vincristine (PCV-3) combination chemotherapy in the\ntreatment of malignant brain tumors. Cancer Treat.\nRep.64,237\n-244.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Macdonald, D.R., Gaspar, L.E., and Cairncross, J.G.\n(1990a) Successful chemotherapy for newly diagnosed aggressive\noligodendroglioma. Arch. Neurol.27,573\n-574.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Macdonald, D.R., Cascino, T.L., Schold, S.C., Jr., and Cairncross,\nJ.G. (1990b) Response criteria for phase II studies of\nsupratentorial malignant glioma. J. Clin. Oncol.8,1277\n-1280.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Maintz, D., Fiedler, K., Koopmann, J., Rollbrocker, B., Nechev, S.,\nLenartz, D., Stangl, A.P., Louis, D.N., Schramm, J., Wiestler, O.D., and von\nDeimling, A. (1997) Molecular genetic evidence for subsets of\noligoastrocytomas. J. Neuropathol. Exp. Neurol.56,1098\n-1104.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Mason, W.P., Krol, G.S., and DeAngelis, L.M. (1996)\nLow-grade oligodendroglioma respond to chemotherapy.\nNeurology46,203\n-207.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Mason, W., Louis, D.N., and Cairncross, J.G. (1997)\nChemosensitive gliomas in adults: Which ones and why? J. Clin.\nOncol.15,3423\n-3426.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Peterson, K., Paleologos, N., Forsyth, P., Macdonald, D.R., and\nCairncross, J.G. (1996) Salvage chemotherapy for\noligodendroglioma. J. Neurosurg.85,597\n-601.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"Soffietti, R., Ruda, R., Bradac, G.B., and Schiffer, D.\n(1998) PCV chemotherapy for recurrent oligodendrogliomas and\noligoastrocytomas. Neurosurgery43,1066\n-1073.","DOI":"10.1212\/WNL.51.4.1140"},{"key":"key\n\t\t\t\t20171013054341_","doi-asserted-by":"crossref","unstructured":"van den Bent, M.J., Kros, J.M., Heimans, J.J., Pronk, L.C., van\nGroeningen, C.J., Krouwer, H.G.J., Taphoorn, M.J.B., Zonnenberg, B.A.,\nTijssen, C.C., Twijnstra, A., Punt, C.J.A., and Boogerd, W.\n(1998) Response rate and prognostic factors of recurrent\noligodendroglioma treated with procarbazine, CCNU, and vincristine\nchemotherapy. Neurology51,1140\n-1145.","DOI":"10.1212\/WNL.51.4.1140"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/2\/2\/114\/13068246\/p114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T05:45:56Z","timestamp":1507873556000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article\/2\/2\/114\/1059855\/Myeloablative-chemotherapy-for-recurrent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4,1]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2000,4,1]]},"published-print":{"date-parts":[[2000,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/2.2.114","relation":{},"ISSN":["1523-5866","1522-8517"],"issn-type":[{"value":"1523-5866","type":"electronic"},{"value":"1522-8517","type":"print"}],"subject":[],"published-other":{"date-parts":[[2000,4]]},"published":{"date-parts":[[2000,4,1]]}}}